Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry
-
Published:2024-02
Issue:2
Volume:23
Page:100721
-
ISSN:1535-9476
-
Container-title:Molecular & Cellular Proteomics
-
language:en
-
Short-container-title:Molecular & Cellular Proteomics
Author:
Gobom Johan,
Brinkmalm Ann,
Brinkmalm GunnarORCID,
Blennow Kaj,
Zetterberg HenrikORCID
Reference149 articles.
1. An English translation of Alzheimer's 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde”;Alzheimer;Clin. Anat.,1995
2. Alzheimer's disease: the amyloid cascade hypothesis;Hardy;Science,1992
3. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study;McDade;Alzheimers Res. Ther.,2022
4. Donanemab in early Alzheimer’s disease;Mintun;N. Engl. J. Med.,2021
5. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Abeta protofibril antibody;Swanson;Alzheimers Res. Ther.,2021
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献